Abstract: Fatty acid synthase (FASN), responsible for the de novo synthesis of fatty acids, has been shown to act as an oncogene in various human cancers. However, the mechanisms by which FASN favors the progression of ovarian carcinoma remain unknown. In this study, we evaluated FASN expression in ovarian cancer and investigated how FASN regulates the aggressiveness of ovarian cancer cells. Our results show that increased FASN is associated with the peritoneal metastasis of ovarian cancers. Over-expression of FASN results in a significant increase of tumor burden in peritoneal dissemination, accompanied by augment in cellular colony formation and metastatic ability. Correspondingly, FASN knockdown using RNA interference in ovarian cancer cells inhibits the migration in vitro and experimental peritoneal dissemination in vivo. Mechanistic studies reveal that FASN promotes Epithelial-mesenchymal Transition (EMT) via a transcriptional regulation of E-cadherin and N-cadherin, which is also confirmed by luciferase promoter activity 
To study the role of FASN in the metastases of human ovarian cancer, we investigated the expression of FASN in human ovarian cancer tissue samples, as well as the function of FASN in human ovarian cancer cell lines. In this study, we demonstrate that elevated FASN expression promotes the malignant properties of ovarian cancer cells in vitro. Knockdown FASN by siRNA significantly suppresses experimental peritoneal metastasis of ovarian cancer.
Results and Discussion

Results
Increased Expression of Fatty Acid Synthase (FASN) Correlated with the Progression and Peritoneal Metastasis of Human Ovarian Cancer
To examine the potential clinical relevance of FASN to ovarian cancer progression, we sought to investigate FASN expression and its association with different clinicopathological parameters using a human ovarian cancer tissue microarray derived from patients with progressive ovarian disease. Normal ovarian tissue and benign ovarian tissue displayed undetectable to very low FASN staining whereas ovarian carcinomas showed FASN immunoreactivity in most cases ( Figure 1a ). The FASN staining score of high-grade carcinomas is significantly higher than that of low-grade carcinomas. Immunohistochemical staining for FASN revealed a correlation between FASN expression levels and ovarian cancer progression ( Figure 1b) . Next, we investigated whether FASN expression is correlated with key clinical parameters in human ovarian cancer. There were no significant correlations between high FASN expression and patient age, histological subtypes (Figure 1c) , however, FASN expression was associated with FIGO stage (p < 0.05) (Figure 1b ). Peritoneal transcoelomic dissemination is the main common metastasis causing the greatest morbidity and mortality in women with this disease, and we next determined the association of FASN expression with peritoneal metastasis. Statistical evaluation of immunoreactivity scores showed that expression of FASN was significantly unregulated in the patients with peritoneal metastasis compared with non-metastasis patients (Figure 1d ). Taken together, these data strongly indicate that enhanced FASN may play a role in the progression of the primary ovarian cancer cell to peritoneal metastasis.
FASN Promoted the Colony Formation of Ovarian Cancer Cell
Given the correlation of FASN expression with clinically relevant features, we investigated FASN as a potential regulator of ovarian cancer cell biological characteristics. Firstly, we tested expression of FASN in a panel of ovarian cancer cell lines. Consistent with results obtained from human tissue arrays, western blot analysis showed high expression of FASN in most ovarian cancer cells (Figure 2a) . Secondly, to examine how FASN affects the biology of ovarian cancer cells, we stably transduced SW-626 cell with an empty vector or FASN plasmid vector, and transduced SKOV-3 cell with control shRNA vector or shFASN vector to generate stable cells. We effectively over-expressed FASN in SW-626 cell and knock-down FASN in SKOV-3 cell (Figure 2b ). SW-626 (control and FASN over-expression) and SKOV-3 cell (control and FASN knockdown) were tested for their ability to grow using colony formation assay. We observed a significant increase in the number of colonies formed when FASN was over-expressed in SW-626 cell (Figure 2c ). Conversely, knock-down FASN decreased the number of colonies formed in SKOV-3 cell (Figure 2d ). Migration and invasion are critical steps in the initial progression of cancer that facilitate metastasis. To elucidate the association of FASN expression and ovarian cancer cell metastasis, we chose to analyze migration using two independent assays, monolayer wound healing and metastasis transwell assay. We first confirmed that overexpression or knockdown of FASN did not affect ovarian cancer cell viability in 24 h. In monolayer migration assays, wound closure of cells with FASN knockdown was modestly inhibited relative to non-target control shRNA-transfected cells (Figure 3a,b) . Next, we analyzed directional migration toward fetal bovine serum (FBS) in transwell migration assays, which is a more relevant assay than wound healing for assessing metastatic potential. Over-expression of FASN significantly increased the migration of SW-626 cell (Figure 3c ). Conversely, knockdown of FASN attenuated the migration of SKOV-3 cell (Figure 3d ). 
FASN Leads to Ovarian Cancer Progression of Invasion Ability through Induction of Epithelial-to-Mesenchymal Transition (EMT)
Invasion and metastasis are considered as associated properties of tumor cells because they use similar processes. To evaluate whether FASN has influence on the invasion-related protein in ovarian cancer cells, we carried out Western blot to detect the expression of MMP2 and MMP9, which can digest various components of extracellular matrix and are crucial to invasion, metastasis and tumorigenesis. Our results showed that overexpression of FASN in ovarian cancer cell line SW-626 enhanced the level of MMP2 and MMP9. Conversely, shRNA knockdown of FASN reduced the level of MMP2 and MMP9 (Figure 5a ). To decipher the underlying mechanisms that mediate an increase of metastatic potential of FASN on ovarian cancer cell, we examined the morphology characteristics of FASN stable transfected cells and shFASN stable transfected cells. Interestingly FASN stably transfected cells showed a scattering phenotype with spindle-shaped and fibroblast-like morphology. Conversely, compared with vector stable cells, shFASN stable SKOV-3 cells showed a round morphology and clump growth status. This suggests that the cells may have epithelial-to-mesenchymal transition (EMT). EMT is one of the mechanisms for cancer cells to acquire metastasis and invasion. A key feature of EMT is the switch from E-cadherin to N-cadherin, cells undergoing EMT downregulate the expression E-cadherin accompanied by an increased expression of N-cadherin which promotes the interaction with endothelial and stromal components [21] . Snail and Slug are the key proteins for the EMT regulation. We detected the slug and snail expression in protein level when FASN was over-expressed or with knockdown. We found that overexpression of FASN significantly increased the slug and snail expression, while knockdown of FASN decreased the expression of slug and snail (Figure 5a ), which indicated that FASN is involved in EMT regulation. In keeping with the morphological changes, our results showed that overexpression of FASN reduced the expression of E-cadherin (an epithelial marker), but increased the expression of N-cadherin (a mesenchymal cell marker) (Figure 5a ). Quantitative results showed that FASN induces EMT related protein in ovarian cancer cells (Figure 5b ). Moreover, EMT was confirmed by quantifying epithelial and mesenchymal markers, E-cadherin, and N-cadherin at mRNA levels (Figure 5c ), which suggests the FASN effect on the EMT-related gene at transcriptional level. To verify the hypothesis, we performed a luciferase assay with an E-cadherin promoter-luciferase reporter construct and a N-cadherin promoter-luciferase reporter construct. As predicted, FASN inhibited the activity of the transfected E-cadherin promoter-reporter and enhanced the activity of the transfected N-cadherin promoter-reporter (Figure 5d ). Apart from the finding, we proposed a model to illustrate the role of FASN-mediated EMT leading to the conversion of ovarian tumors into invasive malignancies ( Figure 6 ). 
Discussion
A number of studies have reported the possible involvement of FASN in human carcinogenesis. Our work for the first time examined the influences and the mechanisms of FASN on the metastasis phenotype of ovarian cancer cells in vitro and in vivo. On the basis of clinical specimen-derived observations, FASN is positively correlated with the peritoneal metastasis. Over-expression of FASN promotes ovarian cancer cell migration in vitro and experimental peritoneal metastasis in vivo. The oncogenic role of FASN in metastasis is evidenced by a transcriptional regulation of the main components of EMT.
A cancer cell has been recognized as presenting altered metabolism with the observation of increased aerobic glycolysis [22, 23] . Fatty acid synthase (FASN) is a key enzyme for the de novo synthesis of long-chain fatty acids from acetyl-CoA, malonyl-CoA, and nicotinamide adenine dinucleotide phosphate [24] . More recently, increased expression of FASN has emerged as a malignant phenotype common to numerous human cancers [6, 16, [25] [26] [27] . In ovarian cancer, other groups have shown that FASN overexpression is critical to the growth and survival of ovarian carcinomas and FASN interacts with ErbB-systems in ovarian cancer cells [26, [28] [29] [30] . However, the role of FASN in metastasis remains unclear in ovarian cancer. Our study shows that FASN is over-expressed in ovarian cancer, which is consistent with previous reports. Unexpectedly, the expression of FASN does not correlate with the tumor histological stage. In our ovarian cancer tissue array assay, FASN protein expression is strongly associated with ovarian cancer FIGO stage and peritoneal metastasis. This suggests that FASN is involved in the aggression and metastasis of the ovarian cancer cell. An anchorage-independent growth is an important prometastatic characteristic of cancer cells. Our data shows that over-expression of FASN increased the number of colonies, while the number of colonies is markedly reduced in FASN deficient cells. Next, both monolayer wound healing and transwell metastasis assay also proved the pro-metastatic role of FASN in ovarian cancer cell. Actually, FASN has been shown to be involved in the metastasis of colon cancer and oral squamous cell carcinomas [6, 15, 31] . Nevertheless, different from other carcinomas, ovarian cancer cell frequently spreads from the primary tumor to peritoneal space by ascites and disseminates within the abdominal cavity by direct extension. In advanced high-grade serous carcinomas, extensive seedy of the peritoneal cavity by tumor cells is often associated with ascites [32] . There is often no clearly identifiable precursor lesion, so the events leading to metastatic disease are poorly understood. Our data of in vivo experiment shows that FASN regulates peritoneal implantation of ovarian cancer. Over-expression of FASN enhanced the peritoneal implantation and produced more ascites; however, silencing of FASN inhibited the peritoneal colonies growth of ovarian cancer cell and has lower ascites. Therefore, our finding suggested that FASN contributes to ovarian cancer peritoneal metastasis by enhancing cancer cell metastasis.
Ovarian cancer is likely to metastasize via intraperitoneal dissemination and intraperitoneal spread appears to be the culmination of a multi-step process. The complex biochemical pathways involved in this process, however, have only just begun to be clarified [33] . Recent evidence suggests that tumor cells likely participate in the epithelial-mesenchymal transition (EMT), through which tumor cells acquire motility and invasion ability. Emerging evidence suggests that EMT plays a crucial role in the aggressiveness in ovarian cancer including increased migration and invasion ability [34] . We also identified a role for FASN down-regulation of E-cadherin, a key regulator of EMT with clinical relevance to aggressive carcinoma. Down-regulation of E-cadherin has several important consequences that are of direct relevance to EMT [35] . In ovarian cancer, E-cadherin mediated the metastasis and progression [36] . Here we show that over-expression of FASN leads to a reduction in E-cadherin, and an increase of N-cadherin in ovarian cancer cell lines at both mRNA and protein levels, which indicates that FASN induces EMT in the ovarian cancer cell. In ovarian tissue, E-cadherin is regulated at both the mRNA and protein levels in part due to differences in the promoter activation in ovarian carcinoma cells [37] . In dual luciferase assay we show that FASN repressed E-cadherin promoter activity and enhanced N-cadherin promoter activity. Our data therefore suggests that FASN induces EMT, highlighting the importance of mechanism in ovarian cancer progression and metastasis. However, we also recognize that there are some issues still needed to be done. The detailed mechanism of transcriptional regulation of E-cadherin or N-cadherin by FASN needs to be further elucidated. A complete understanding of the role of FASN in controlling EMT in tumors is crucial for dissecting the beneficial use of FASN emerging as a potential therapeutic target in ovarian cancer.
Experimental Section
Patients and Tissue Samples
Ovarian tumors were obtained from a cohort of patients treated at Xinhua Hospital, affiliated with Shanghai Jiaotong University School of Medicine, China, between 2010 and 2013. The median age of the patients was 52.8 years. All patients were diagnosed by pathological analyses based on the International Union Against Cancer (UICC) tumor node metastasis (TNM) stage system. Tissue samples (68) from primary tumors and matched adjacent non-neoplastic ovarian tissues were collected and prepared for tissue microarray (TMA). Fresh-frozen tissues were collected and immediately snap-frozen for protein analyses. The study protocol conformed to the ethical guidelines of the Declaration of Helsinki and was approved by the Ethics Committee of Xinhua Hospital (No. XHEC-D-2010-092; 3 May 2010), Shanghai Jiaotong University School of Medicine. Before inclusion in the study, all patients provided written informed consent.
Cell Culture and Transfection
Human ovarian cancer cell lines SW-626, SKOV-3, and OVCAN3 were obtained from the the American Type Culture Collection (ATCC; Manassas, VA, USA). HO8910, HO8910M were obtained from the Chinese Academy of Sciences Cell Bank of Type Culture Collection (Shanghai, China). The cells were routinely cultured in Dulbecco's modified Eagle's medium (DMEM) media supplemented with 10% fetal calf serum, 100 U/mL penicillin and 100 mg/mL streptomycin (Gibco, Grand Island, NY, USA) in 5% CO 2 at 37 °C. The cells used for our experiments were in the log-phase of growth and were negative for mycoplasma and endotoxin, as confirmed by PCR. SW-626 cells were stably transfected with FASN-overexpression construct (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) and control construct, selected using puromycin (Life Technologies, Grand Island, NY, USA), and SKOV-3 cells were stable transfected with shFASN construct (OriGene, Rockville, MD, USA) and control shRNA construct, selected using puromycin (Life Technologies).
Quantitative Real-Time PCR
Quantitative real-time PCR analysis was carried out to detect the mRNA expression of E-cadherin and N-cadherin. Total RNA extraction from ovarian tissue was performed with Trizol Reagent (Life Technologies). Then, RNA was reverse transcribed and quantified by real-time PCR using the Applied Biosystems 7900 System (Applied Biosystems, Foster City, CA, USA). Sequences of primers used for quantitative Real-time PCR were listed as: E-cadherin: forward, 5'-ATTAAC CTCACCAATCCTT-3'; reverse, 5'-TTACACCTTGACCTAACG-3'. N-cadherin: forward, 5'-GTA GCATAATCACTTGTT-3'; reverse, 5'-GTTACATCCACTTCTATT-3'. Additionally GAPDH was used as an endogenous reference gene (forward, 5'-ATTCCACCCATGGCAAATTC-3'; reverse, 5'-GCA TCGCCCCACTTGATT-3').
Immunohistochemical Staining
Standard immunohistochemical procedures were performed using the VECTASTAIN Elite ABC system (Vector Laboratories, Burlingame, CA, USA) according to the manufacturer's protocol and performed as previously described [38] . Anti-FASN polyclonal antibody (Abcam, Cambridge, MA, USA) was used as primary antibody. The staining intensity (0, no staining; 1, weak staining; 2, moderate staining; and 3, intense staining) and the proportion of stained cells (0, no staining; 1, <10% staining; 2, between 11% and 33% staining; 3, between 34% and 66% staining; and 4, >67% staining) were semiquantitatively determined. The intensity and the percentage of positive cell scores were multiplied (0-12) and classified into three groups: weak (0-4), moderate (5-8) and strong (9) (10) (11) (12) . All slides were scored by two observers blinded to the pathology and the clinical features.
Western Blot Analysis
Western blot analyses were performed as previously described [38] . Briefly, the cells were lysed and cell extracts were prepared. Cell homogenates were boiled, and then the FASN protein was separated by SDS-PAGE (6%), and others proteins were separated in gel of 12% SDS-PAGE. After overnight incubation with anti-FASN, anti-Slug, anti-snail, anti-MMP2, or anti-MMP9 (Cell Signaling Technology, Beverly, MA, USA), the membranes were incubated with IRDye 800 goat anti-rabbit or IRDye 680 goat anti-mouse secondary antibodies (LI-COR Biosciences, Lincoln, NE, USA). The targeted proteins were detected and quantified on a Li-COR Odyssey infrared imaging system (LI-COR Biosciences).
Plate Colony Formation Assay
For the plate colony formation assay, the cells were plated into a 6-well tissue culture plate (500 cells/well) and incubated at 37 °C for 8 days. The resulting colonies were rinsed with 1× PBS, fixed with methanol for 10 min, and stained with crystal violet. The colonies were photographed and counted for three independent experiments.
Intraperitoneal Xenograft Mouse Model
An intraperitoneal ovarian cancer cell xenograft was used with the approval obtained by the Ethics Committee of Xinhua Hospital (No. XHEC-D-2010-092; 3 May 2010), Shanghai Jiaotong University School of Medicine. Non-obese diabetic/severe combined immunodeficiency (NOD/SCID) mice were purchased from the Shanghai Laboratory Animal Commission of the Chinese Academy of Science, Shanghai, China. NOD/SCID mice at 6 weeks of age were injected intraperitoneally with ovarian cancer cells (1 × 10 6 cells/0.2 mL). All injection-treated mice were fed for 8 weeks after injection. At the end of 8 weeks, the mice were sacrificed and each tumor burden in the peritoneal cavity was weighed, and the amount of ascites were collected and counted. All experimental use of animals complied with the guidelines of Animal Care at Xinhua Hospital, Shanghai Jiaotong University School of Medicine (Shanghai, China).
Dual Luciferase Reporter Assay
E-Cadherin and N-cadherin promoter activity was determined using E-cadherin or N-cadherin luciferase reporter construct (Ecad-Luc or Ncad-Luc), which encoding the human E-cadherin 5' promoter (−178 to +92) or human N-cadherin 5' promoter (−860 to +20) in pGL3basic (Promega, Madison, WI, USA). Ovarian cancer cells were plated in 24-well plates and transfected with Ecad-Luc or Ncad-Luc and its control plasmid (pRL-TK). At 36 h post transfection, cells were dissolved with passive lysis buffer and luciferase activities were measured using a Dual-Luciferase Reporter Assay System (Promega, Madison, WI, USA) and a microplate luminometer (Promega). The firefly luciferase activities were corrected by the corresponding renilla luciferase activities. Results are representative of three independent experiments.
Statistical Analysis
The data were expressed as the mean ± S.E. of means (S.E.M.). The statistical significance of the difference between two means was assessed using Student's t-test, and the one-way ANOVA with Tukey's post test was performed for multiple comparisons. All the statistical analyses were performed using GraphPad Prism version 5.0 for Windows (GraphPad Software, San Diego, CA, USA), and statistical significance was set at * p < 0.05; ** p < 0.01.
Conclusions
In summary, the authors have provided evidence that higher FASN expression is related to the aggressiveness and peritoneal metastasis of ovarian cancer cells. The authors also propose a probable model by which FASN regulates the transcription of E-cadherin/N-cadherin and by which FASN-mediated EMT provides a mechanism of escape for the primary cancer cell to disseminate, ensuring cell survival in the peritoneal cavity. These data provide support for the role of FASN inducing EMT and also as a therapeutic target for ovarian cancer.
